Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein.

Rad M, Burggraaf J, Sitruk-Ware RL, de Kam ML, Cohen AF, Kluft C

OBJECTIVE & STUDY DESIGN: In a parallel design, 23 and 22 healthy pre-menopausal women were randomly administered a contraceptive vaginal ring (CVR) delivering 150/15 μg Nestorone®/ethinyl estradiol (EE) daily or an oral contraceptive (OC) containing levonorgestrel and EE (150/30 μg) for three cycles, to compare the effects on C-reactive protein and other markers of inflammation. ANCOVA was performed with baseline values as covariate.